Therapeutic outcomes of Empiric Vancomycin in Febrile Neutropenia of Hematologic Malignancy Patients

• Conditions: Adult Inpatients with hematologic malignancy who developed febrile neutropenia; Febrile neutropenia, Vancomycin, Hematologic malignancy

• Registration Number: TCTR20221029001
• Lead Sponsor: /A

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-10-29
• Study Completion: 2024-04-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending (Not yet recruiting)
• Sex: All
• Target Recruitment: 290

Inclusion Criteria

1. Hematologic malignancy adult patients who admitted in Siriraj hospital
2. Diagnosed as febrile neutropenia as definition of IDSA 2010

Exclusion Criteria

1. Trend to cannot evaluated outcome patient ex. palliative care, against advice

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Treatment failure 72 hours after empiric antibiotics absence of improvement or deterioration in WBC, BT or SBP and any clinical parameters

Secondary Outcome Measures

Name	Time	Method
/A N/A N/A